Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. (Q51062974)

From Wikidata

Jump to navigation Jump to search

scientific article published on 17 April 2013

Language	Label	Description	Also known as
English	Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event.	scientific article published on 17 April 2013

Statements

scholarly article

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Lipid profiles are associated with lesion formation over 24 months in interferon-β treated patients following the first demyelinating event. (English)

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

0 references

Dana Horáková

3

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Niels Bergsland

13

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Michaela Tyblova

object named as

Michaela Tyblova

11

0 references

object named as

Eva Havrdova

4

0 references

Bianca Weinstock-Guttman

1

object named as

Bianca Weinstock-Guttman

1 reference

Europe PubMed Central

28 March 2018

Miriam Tamaño-Blanco

10

object named as

Miriam Tamaño-Blanco

1 reference

Europe PubMed Central

28 March 2018

Murali Ramanathan

18

object named as

Murali Ramanathan

1 reference

Europe PubMed Central

28 March 2018

Robert Zivadinov

2

object named as

Robert Zivadinov

1 reference

Europe PubMed Central

28 March 2018

Darlene Badgett

9

object named as

Darlene Badgett

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

14

object named as

Laura Willis

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Jan Krásenský

15

object named as

Jan Krasensky

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Manuela Vaněčková

16

object named as

Manuela Vaneckova

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

17

object named as

Zdenek Seidl

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

author name string

Jun Qu

5

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Grace Shyh

6

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Elizabeth Lakota

7

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Kerri O'Connor

8

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Sara Hussein

12

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

language of work or name

0 references

publication date

17 April 2013

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Journal of Neurology, Neurosurgery and Psychiatry

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

84

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

11

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

1186-1191

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Paraoxonase 1 activity in different types of multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

The immune system in atherosclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Smoke exposure increases the risk for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Abnormal subcortical deep-gray matter susceptibility-weighted imaging filtered phase measurements in patients with multiple sclerosis: a case-control study.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Structural modifications of HDL and functional consequences

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Interferon-beta treatment decreases cholesterol plasma levels in multiple sclerosis patients

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Ultra-high-field imaging distinguishes MS lesions from asymptomatic white matter lesions

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Associations between subclinical thyroid disease and metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

The effect of thyroid disorders on lipid levels and metabolism

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Lipid lowering with thyroid hormone and thyromimetics

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Validation of a self-report comorbidity questionnaire for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Triiodothyronine administration ameliorates the demyelination/remyelination ratio in a non-human primate model of multiple sclerosis by correcting tissue hypothyroidism.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Normal timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1 (TRalpha1).

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

The T3-induced gene KLF9 regulates oligodendrocyte differentiation and myelin regeneration

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Inter-dependence of vitamin D levels with serum lipid profiles in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Interferon-β and serum 25-hydroxyvitamin D interact to modulate relapse risk in MS.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Oral simvastatin treatment in relapsing-remitting multiple sclerosis

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Simvastatin as add-on therapy to interferon β-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial.

1 reference

https://api.crossref.org/works/10.1136%2FJNNP-2012-304740

21 January 2018

Identifiers

10.1136/JNNP-2012-304740

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

release_gpvw6fnz55erpnkh2rxblxu2zq

1 reference

https://api.fatcat.wiki/v0/release/gpvw6fnz55erpnkh2rxblxu2zq

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

28 March 2018

http://europepmc.org/abstract/MED/23595944

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51062974&oldid=1859548938"